Key result
Manifesting female carriers of Duchenne muscular dystrophy presented with inconsistent clinical features, and multiplex ligation-dependent probe amplification was essential for accurate genetic diagnosis.
Case Report (n=3)
No
MLPA and dystrophin immunohistochemistry are essential for accurately diagnosing manifesting female carriers of Duchenne muscular dystrophy, who may present with inconsistent clinical features and negative conventional PCR results.
This is the authors' abstract. We don't add key points for this paper.
Duchenne muscular dystrophy usually affects males. However, females are also affected in rare instances. Approximately 8% of female Duchenne muscular dystrophy (DMD) carriers are manifesting carriers and have muscle weakness to some extent. We investigated the clinical features of 3 female patients with dystrophinopathy diagnosed by clinical, pathological, and genetic studies at our neuromuscular disease clinic. The onset age of manifesting symptoms varied (8-28 years). Muscle weakness grade varied as follows: patient 1 showed asymmetrical bilateral proximal upper and lower extremities weakness, patient 2 showed asymmetrical bilateral upper extremities weakness similar to scapulohumoral muscular dystrophy, and patient 3 had only bilateral asymmetric proximal lower extremities weakness. Two patients had familial histories of DMD (their sons were diagnosed with DMD), but the 1 remaining patient had no familial history of DMD. The serum creatine kinase level was elevated in all patients, but it was not correlated with muscular weakness. An electromyography study showed findings of myopathy in all patients. One patient was diagnosed with a DMD carrier by a muscle biopsy with an immunohistochemical stain (dystrophin). The remaining 2 patients with familial history of DMD were diagnosed by multiplex ligation-dependent probe amplification (MLPA). There were inconsistent clinical features in the female carriers. An immunohistochemical analysis of dystrophin could be useful for female carrier patients. Also, multiplex ligation-dependent probe amplification is essential for the diagnosis of a manifesting female carrier DMD in female myopathic patients because conventional multiplex PCR could not detect the duplication and is less accurate compared to MLPA.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to MLPA testing in suspected manifesting DMD carriers with negative PCR; leaves open need for larger validation studies.
No takes yet. Share an insight, caveat, or question.
Song et al. (2010) conducted a case report in Duchenne muscular dystrophy (manifesting female carriers) (n=3). Multiplex ligation-dependent probe amplification (MLPA) and immunohistochemistry was evaluated on Clinical, pathological, and genetic features. Manifesting female carriers of Duchenne muscular dystrophy presented with inconsistent clinical features, and multiplex ligation-dependent probe amplification was essential for accurate genetic diagnosis.
Synapse has enriched 10 related papers. Consider them for comparative context: